Michael J. Zhang

Michael J. Zhang

Auto-generated profile, based on publicly available information

Michael J. Zhang

Lillehei Heart Institute and Department of Medicine (Cardiovascular Division), University of Minnesota Medical School, Minneapolis (M.J.Z., L.Y.C.).

Research Focus & Metrics

Academic Career Length

19Years (2008-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 February 2018 in Human Gene Therapy
Verified
Journal Article
Closed access
WZWei-Wei Zhang
Wei-Wei Zhang
LLLongjiang Li
Longjiang Li
DLDinggang Li
Dinggang Li
JLJiliang Liu
Jiliang Liu
XLXiuqin Li
Xiuqin Li
DLDominic Man-Kit Lam
Dominic Man-Kit Lam
Gendicine (recombinant human p53 adenovirus), developed by Shenzhen SiBiono GeneTech Co. Ltd., was approved in 2003 by the China Food and Drug Administration (CFDA) as a first-in-class gene therapy product to treat head and neck cancer, and entered the commercial market in 2004. Gendicine is a biological therapy that is delivered via minimally invasive intratumoral injection, as well as by intracavity or intravascular infusion. The wild-type (wt) p53 protein expressed by Gendicine-transduced cells is a tumor suppressor that is activated by cellular stress, and mediates cell-cycle arrest and DNA repair, or induces apoptosis, senescence, and/or autophagy, depending upon cellular stress conditions. Based on 12 years of commercial use in >30,000 patients, and >30 published clinical studies, Gendicine has exhibited an exemplary safety record, and when combined with chemotherapy and radiotherapy has demonstrated significantly higher response rates than for standard therapies alone. In addition to head and neck cancer, Gendicine has been successfully applied to treat various other cancer types and different stages of disease. Thirteen published studies that include long-term survival data showed that Gendicine combination regimens yield progression-free survival times that are significantly longer than standard therapies alone. Although the p53 gene is mutated in >50% of all human cancers, p53 mutation status did not significantly influence efficacy outcomes and long-term survival rate for Ad- p53 -treated patients. To date, Shenzhen SiBiono GeneTech has manufactured 41 batches of Gendicine in compliance with CFDA QC/QA requirements, and 169,571 vials (1.0 × 10 12 vector particles per vial) have been used to treat patients. No serious adverse events have been reported, except for vector-associated transient fever, which occurred in 50–60% of patients and persisted for only a few hours. The manufacturing accomplishments and clinical experience with Gendicine, as well as the understanding of its cellular mechanisms of action and implications, could provide valuable insights for the international gene therapy community and add valuable data to promote further developments and advancements in the gene therapy field.

17 January 2013 in Diabetes
Verified
Journal Article
Open access
PDF file
YTYunan Tang
Yunan Tang
MZMichael J. Zhang
Michael J. Zhang
JHJason Hellmann
Jason Hellmann
MKMadhavi Kosuri
Madhavi Kosuri
ABAruni Bhatnagar
Aruni Bhatnagar
MSMatthew Spite
Matthew Spite
Obesity and type 2 diabetes are emerging global epidemics associated with chronic, low-grade inflammation. A characteristic feature of type 2 diabetes is delayed wound healing, which increases the risk of recurrent infections, tissue necrosis, and limb amputation. In health, inflammation is actively resolved by endogenous mediators, such as the resolvins. D-series resolvins are generated from docosahexaenoic acid (DHA) and promote macrophage-mediated clearance of microbes and apoptotic cells. However, it is not clear how type 2 diabetes affects the resolution of inflammation. Here, we report that resolution of acute peritonitis is delayed in obese diabetic (db/db) mice. Altered resolution was associated with decreased apoptotic cell and Fc receptor–mediated macrophage clearance. Treatment with resolvin D1 (RvD1) enhanced resolution of peritonitis, decreased accumulation of apoptotic thymocytes in diabetic mice, and stimulated diabetic macrophage phagocytosis. Conversion of DHA to monohydroxydocosanoids, markers of resolvin biosynthesis, was attenuated in diabetic wounds, and local application of RvD1 accelerated wound closure and decreased accumulation of apoptotic cells and macrophages in the wounds. These findings support the notion that diabetes impairs resolution of wound healing and demonstrate that stimulating resolution with proresolving lipid mediators could be a novel approach to treating chronic, nonhealing wounds in patients with diabetes.

21 August 2012 in Annual Review of Nutrition
Verified
Journal Article
Closed access
MZMichael J. Zhang
Michael J. Zhang
MSMatthew Spite
Matthew Spite
Omega-3 polyunsaturated fatty acids (PUFAs) are essential to health, and deficiencies in these PUFAs are linked to chronic disease. Although important insights into the diverse biological roles of PUFAs have been made, the mechanistic basis underlying their protective actions is still emerging. Studies over the past decade have elucidated that omega-3 PUFAs are enzymatically converted into bioactive autacoids that have inflammation-resolving properties. Among these, resolvins have emerged as an important family that has potent and stereospecific immunomodulatory roles, elucidation of which has contributed to a growing body of literature demonstrating that resolution of acute inflammation is an active process. In addition to their direct interactions with immune cells, resolvins have effects on nonimmune cells as well, suggesting a much broader role in biological systems than originally appreciated. In this review, we describe the endogenous biosynthesis and immunomodulatory actions of resolvins and highlight their emerging roles in health and disease.

30 August 2016 in Circulation
Verified
Journal Article
Open access
PDF file
MZMichael J. Zhang
Michael J. Zhang
BSBrian E. Sansbury
Brian E. Sansbury
JHJason Hellmann
Jason Hellmann
JBJames F. Baker
James F. Baker
LGLuping Guo
Luping Guo
MSMatthew Spite
Matthew Spite
Background: Resolvins are lipid mediators generated by leukocytes during the resolution phase of inflammation. They have been shown to regulate the transition from inflammation to tissue repair; however, it is unknown whether resolvins play a role in tissue revascularization following ischemia. Methods: We used a murine model of hind limb ischemia (HLI), coupled with laser Doppler perfusion imaging, microcomputed tomography, and targeted mass spectrometry, to assess the role of resolvins in revascularization and inflammation resolution. Results: In mice undergoing HLI, we identified resolvin D2 (RvD2) in bone marrow and skeletal muscle by mass spectrometry (n=4–7 per group). We also identified RvD2 in skeletal muscle biopsies from humans with peripheral artery disease. Monocytes were recruited to skeletal muscle during HLI and isolated monocytes produced RvD2 in a lipoxygenase-dependent manner. Exogenous RvD2 enhanced perfusion recovery in HLI and microcomputed tomography of limb vasculature revealed greater volume, with evidence of tortuous arterioles indicative of arteriogenesis (n=6–8 per group). Unlike other treatment strategies for therapeutic revascularization that exacerbate inflammation, RvD2 did not increase vascular permeability, but reduced neutrophil accumulation and the plasma levels of tumor necrosis factor-α and granulocyte macrophage colony-stimulating factor. In mice treated with RvD2, histopathologic analysis of skeletal muscle of ischemic limbs showed more regenerating myocytes with centrally located nuclei. RvD2 enhanced endothelial cell migration in a Rac-dependent manner, via its receptor, GPR18, and Gpr18 -deficient mice had an endogenous defect in perfusion recovery following HLI. Importantly, RvD2 rescued defective revascularization in diabetic mice. ConclusionS: RvD2 stimulates arteriogenic revascularization during HLI, suggesting that resolvins may be a novel class of mediators that both resolve inflammation and promote arteriogenesis.

1 August 2013 in The Journal of Immunology
Verified
Journal Article
Closed access
PDF file
JHJason Hellmann
Jason Hellmann
MZMichael J. Zhang
Michael J. Zhang
YTYunan Tang
Yunan Tang
MRMadhavi Rane
Madhavi Rane
ABAruni Bhatnagar
Aruni Bhatnagar
MSMatthew Spite
Matthew Spite
Extensive evidence indicates that nutrient excess associated with obesity and type 2 diabetes activates innate immune responses that lead to chronic, sterile low-grade inflammation, and obese and diabetic humans also have deficits in wound healing and increased susceptibility to infections. Nevertheless, the mechanisms that sustain unresolved inflammation during obesity remain unclear. In this study, we report that saturated free fatty acids that are elevated in obesity alter resolution of acute sterile inflammation by promoting neutrophil survival and decreasing macrophage phagocytosis. Using a targeted mass spectrometry–based lipidomics approach, we found that in db/db mice, PGE2/D2 levels were elevated in inflammatory exudates during the development of acute peritonitis. Moreover, in isolated macrophages, palmitic acid stimulated cyclooxygenase-2 induction and prostanoid production. Defects in macrophage phagocytosis induced by palmitic acid were mimicked by PGE2 and PGD2 and were reversed by cyclooxygenase inhibition or prostanoid receptor antagonism. Macrophages isolated from obese-diabetic mice expressed prostanoid receptors, EP2 and DP1, and contained significantly higher levels of downstream effector, cAMP, compared with wild-type mice. Therapeutic administration of EP2/DP1 dual receptor antagonist, AH6809, decreased neutrophil accumulation in the peritoneum of db/db mice, as well as the accumulation of apoptotic cells in the thymus. Taken together, these studies provide new insights into the mechanisms underlying altered innate immune responses in obesity and suggest that targeting specific prostanoid receptors may represent a novel strategy for resolving inflammation and restoring phagocyte defects in obese and diabetic individuals.

1 January 2015 in Prostaglandins & Other Lipid Mediators
Verified
Journal Article
Closed access
JHJason Hellmann
Jason Hellmann
YTYunan Tang
Yunan Tang
MZMichael J. Zhang
Michael J. Zhang
THTsonwin Hai
Tsonwin Hai
ABAruni Bhatnagar
Aruni Bhatnagar
MSMatthew Spite
Matthew Spite